Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice TargetHot
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.